Summary:
- Phil, a software-driven pharmaceutical commercialization platform in San Francisco, secured $60 million in growth debt financing from K2 HealthVentures to enhance its AI integration and expand its customer base.
- The company’s platform facilitates therapy deployment for pharmaceutical manufacturers by incorporating digital stakeholder experiences, patient access services, market access tools, and flexible distribution models.
- Phil has experienced significant growth since its Series D financing in 2021, with a substantial increase in prescription volumes, revenue growth, and positive operating cash flow.
—
Article:
Phil Secures $60M in Growth Debt Financing from K2 HealthVentures
Phil, a leading software-driven pharmaceutical commercialization platform based in San Francisco, recently announced a major milestone in its funding journey. The company received a significant investment of $60 million in growth debt financing from K2 HealthVentures (K2HV). This injection of capital is expected to fuel Phil’s efforts in integrating artificial intelligence across its platform and expanding its customer base in various therapeutic areas.
Innovative Platform Revolutionizing Therapy Deployment
Led by Founder and CEO Deepak Thomas, Phil is known for its innovative approach to therapy deployment. The platform offers pharmaceutical manufacturers a comprehensive solution to deliver therapy access to patients. By leveraging digital stakeholder experiences, patient access services, market access tools, and flexible distribution models, Phil streamlines the process of getting essential treatments to those in need.
Impressive Growth and Financial Performance
Since securing its Series D financing led by Warburg Pincus in 2021, Phil has experienced remarkable growth in various aspects of its business. The company has seen prescription volumes soar by over 10 times, ending 2024 with a remarkable 150% year-over-year net revenue growth. Additionally, Phil has achieved a positive operating cash flow, showcasing its financial stability and potential for continued success in the pharmaceutical industry.
In conclusion, Phil’s recent funding milestone and impressive track record of growth highlight the company’s position as a key player in the pharmaceutical commercialization space. With a focus on innovation, technology integration, and customer expansion, Phil is poised for further success in the coming years.
Published by FinSMEs on 09/07/2025
